JP2013507438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507438A5 JP2013507438A5 JP2012534237A JP2012534237A JP2013507438A5 JP 2013507438 A5 JP2013507438 A5 JP 2013507438A5 JP 2012534237 A JP2012534237 A JP 2012534237A JP 2012534237 A JP2012534237 A JP 2012534237A JP 2013507438 A5 JP2013507438 A5 JP 2013507438A5
- Authority
- JP
- Japan
- Prior art keywords
- uric acid
- subject
- compound
- hydrogen
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 38
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 38
- 229940116269 uric acid Drugs 0.000 claims 38
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 13
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 230000029142 excretion Effects 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000008280 blood Substances 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 239000003638 chemical reducing agent Substances 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 201000001431 Hyperuricemia Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 208000028698 Cognitive impairment Diseases 0.000 claims 3
- 208000007530 Essential hypertension Diseases 0.000 claims 3
- 201000005569 Gout Diseases 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000000913 Kidney Calculi Diseases 0.000 claims 3
- 206010029148 Nephrolithiasis Diseases 0.000 claims 3
- 241000223960 Plasmodium falciparum Species 0.000 claims 3
- 108010092464 Urate Oxidase Proteins 0.000 claims 3
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000008085 renal dysfunction Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 238000011287 therapeutic dose Methods 0.000 claims 3
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000002028 premature Effects 0.000 claims 2
- NPQOSTVWLGSWEB-UHFFFAOYSA-N 2,4-dimethyl-3-[[3-(2h-tetrazol-5-yl)phenoxy]methyl]phenol Chemical compound CC1=CC=C(O)C(C)=C1COC1=CC=CC(C=2NN=NN=2)=C1 NPQOSTVWLGSWEB-UHFFFAOYSA-N 0.000 claims 1
- BGZVYMHPTSSBHY-UHFFFAOYSA-N 2-[3-[(2,6-dimethyl-3-nitrophenyl)methoxy]phenyl]acetic acid Chemical compound CC1=CC=C([N+]([O-])=O)C(C)=C1COC1=CC=CC(CC(O)=O)=C1 BGZVYMHPTSSBHY-UHFFFAOYSA-N 0.000 claims 1
- DJNVBHUDDFJRHE-UHFFFAOYSA-N 2-[3-[(3-hydroxy-2,6-dimethylphenyl)methoxy]-4-methylphenyl]acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1OCC1=C(C)C=CC(O)=C1C DJNVBHUDDFJRHE-UHFFFAOYSA-N 0.000 claims 1
- NJFFVVMRASKBMC-UHFFFAOYSA-N 2-[3-[(3-methoxy-2,6-dimethylphenyl)methoxy]-4-methylphenyl]acetic acid Chemical compound COC1=CC=C(C)C(COC=2C(=CC=C(CC(O)=O)C=2)C)=C1C NJFFVVMRASKBMC-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- -1 perfluoromethoxy, hydroxy Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 0 *c1cc(*)c(*)c(*=*)c1* Chemical compound *c1cc(*)c(*)c(*=*)c1* 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25109809P | 2009-10-13 | 2009-10-13 | |
| US61/251,098 | 2009-10-13 | ||
| PCT/US2010/051781 WO2011046800A1 (en) | 2009-10-13 | 2010-10-07 | 3-substituted compounds for reducing uric acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507438A JP2013507438A (ja) | 2013-03-04 |
| JP2013507438A5 true JP2013507438A5 (https=) | 2013-11-21 |
| JP5806221B2 JP5806221B2 (ja) | 2015-11-10 |
Family
ID=43876448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534237A Expired - Fee Related JP5806221B2 (ja) | 2009-10-13 | 2010-10-07 | 尿酸を減少させる３−置換化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8546448B2 (https=) |
| EP (1) | EP2488020B1 (https=) |
| JP (1) | JP5806221B2 (https=) |
| CN (1) | CN102573462B (https=) |
| WO (1) | WO2011046800A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012033720A1 (en) | 2010-09-08 | 2012-03-15 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| US8808403B2 (en) * | 2010-09-15 | 2014-08-19 | Kemet Electronics Corporation | Process for solid electrolytic capacitors using polymer slurries |
| KR102240158B1 (ko) | 2013-05-13 | 2021-04-15 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도 |
| CN104230833B (zh) * | 2014-10-07 | 2016-01-20 | 张远强 | 含腈基的四氮唑乙酸类化合物、其制备方法及用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4024253A (en) * | 1973-04-20 | 1977-05-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Treatment of elevated histamine and uric acid levels |
| GB1482195A (en) * | 1973-08-23 | 1977-08-10 | Beecham Group Ltd | Biologically active phenyl(thio)ether derivatives |
| US5274000A (en) * | 1982-10-19 | 1993-12-28 | Kotobuki Seiyaku Company Limited | Benzofuran and benzothiophene derivatives, anti-hyperuricemia agents |
| FR2631827B1 (fr) * | 1988-05-27 | 1992-03-27 | Delalande Sa | Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique |
| US5064830A (en) * | 1990-08-02 | 1991-11-12 | Pfizer Inc. | Lowering of blood uric acid levels |
| MXPA03011558A (es) * | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| US7078423B2 (en) * | 2002-07-18 | 2006-07-18 | Inotek Pharmaceuticals Corporation | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| MXPA05008600A (es) * | 2003-02-13 | 2005-11-04 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| US7419980B2 (en) * | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
| EP1841749A1 (en) * | 2004-09-02 | 2007-10-10 | Metabasis Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
| US20060211697A1 (en) * | 2004-12-08 | 2006-09-21 | Liren Huang | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents |
| EP1849465A4 (en) * | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| EP2098517B1 (en) * | 2006-12-01 | 2013-12-18 | Msd K.K. | Novel phenyl-isoxazol-3-ol derivative |
| RU2009137190A (ru) * | 2007-03-08 | 2011-04-20 | Плексксикон, Инк. (Us) | Соединения, обладающие активностью в отношении ppar |
| JP5339545B2 (ja) * | 2008-03-13 | 2013-11-13 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる化合物及び方法 |
| MX2010011603A (es) * | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
| GB0810615D0 (en) * | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
| GB0810617D0 (en) * | 2008-06-10 | 2008-07-16 | Glaxo Group Ltd | Novel pharmaceutical |
-
2010
- 2010-10-07 WO PCT/US2010/051781 patent/WO2011046800A1/en not_active Ceased
- 2010-10-07 JP JP2012534237A patent/JP5806221B2/ja not_active Expired - Fee Related
- 2010-10-07 EP EP10823855.1A patent/EP2488020B1/en active Active
- 2010-10-07 CN CN201080046070.0A patent/CN102573462B/zh not_active Expired - Fee Related
-
2011
- 2011-09-15 US US13/501,338 patent/US8546448B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011519865A5 (https=) | ||
| JP2011515349A5 (https=) | ||
| JP6594400B2 (ja) | 肝障害を処置するための１，３−ジフェニルプロパ−２−エン−１−オン誘導体の使用 | |
| RU2010148762A (ru) | Тетразольные соединения для снижения концентрации мочевой кислоты | |
| RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
| KR101567885B1 (ko) | 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물 | |
| JP7053478B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| ES2752039T3 (es) | Agente terapéutico para la dislipidemia | |
| JP2010522710A5 (https=) | ||
| JP2012525393A5 (https=) | ||
| AU2013217933B2 (en) | Methods of treating fibrosis | |
| JP2004525179A (ja) | ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置 | |
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| JP2009530398A5 (https=) | ||
| JP2014502979A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP2013508282A (ja) | ウイルス感染のための併用療法処置 | |
| JP2009528275A5 (https=) | ||
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| JP2013507438A5 (https=) | ||
| AU2020201980A1 (en) | Combination of FXR agonists | |
| JP2017519028A5 (https=) | ||
| JP2009502777A5 (https=) | ||
| JP2004533415A5 (https=) | ||
| JP2007519633A5 (https=) |